On-Demand CME Videos
FC24: Is EASI 75 Good Enough or Can We Do Better? Elevating Efficacy and Long-Term Safety With JAK Inhibitors in Moderate-to-Severe Atopic Dermatitis: An Online Activity
About
FC24: Is EASI 75 Good Enough or Can We Do Better? Elevating Efficacy and Long-Term Safety With JAK Inhibitors in Moderate-to-Severe Atopic Dermatitis: An Online Activity
This activity is supported by an educational grant from AbbVie.
Availability
In order to ensure educational material is relevant, educational materials will expire after a certain time period. This course will be available for the following dates:
December 15, 2024
December 15, 2025
Learning Objectives
At the completion of this activity, participants should be better able to:
Discuss optimization of treatment selection based on head-to-head data on systemic Janus kinase (JAK) inhibitors in moderate-to-severe atopic dermatitis
Review long-term benefit-risk profile for systemic JAK inhibitors for the treatment of moderate-to-severe AD
Identify strategies to employ new efficacy targets in the treat-to-target framework for the management of moderate-to-severe atopic dermatitis
Describe shared decision-making approaches for managing moderate-to-severe atopic dermatitis with systemic JAK inhibitors
Intended Audience
Faculty
Christopher Bunick, MD, PhD
Associate Professor of Dermatology
Yale University School of Medicine
New Haven, CT
Brad Glick, DO, MPH
Program Director, Dermatology Residency
Larkin Community Hospital Palm Springs Campus
Hialeah, FL
Alexandra Golant, MD
Medical Director, Dermatology Faculty Practice
Associate Director, Residency Program
Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, NY
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of University of Nevada, Reno School of Medicine and CMEsquared. The University of Nevada, Reno School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The University of Nevada, Reno School of Medicine designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures & Disclaimers
Disclosures are as follows:
Grant/Research Support: Almirall
Ownership interest: Top MD stock
Advisory Board: Abbvie, Amgen, Arcutis, BMS, Dermavant, Galderma, Incyte, Janssen, LEO Pharma, Lilly, Pfizer, Regeneron, Sanofi
Consultant: Abbvie, Arcutis, Dermavant, Galderma, Lilly, Regeneron, Sanofi
Speakers’ Bureau Honoraria: Abbvie, Arcutis, Dermavant, Galderma, Incyte, Lilly, Pfizer, Regeneron, Sanofi
The University of Nevada, Reno School of Medicine discloses that all relevant conflicts have been satisfactorily mitigated.